From snake venom toxins to therapeutics - Cardiovascular examples

Toxicon

Volumn 59, Issue 4, 2012, Pages 497-506

  Koh, Cho Yeow ^a   Kini, R Manjunatha ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti cancer; Anti hypertensive agents; Antithrombotic agents; Drug design; Drug discovery; Toxins to drugs; Toxins to therapeutics

Indexed keywords

ALFIMEPRASE; ANCROD; BATROXOBIN; BRADYKININ; CALCISEPTINE; CALCIUM CHANNEL L TYPE; CAPTOPRIL; CONTORTROSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISINTEGRIN; EPTIFIBATIDE; FIBRINOGEN; NATRIURETIC FACTOR; NESIRITIDE; NIFEDIPINE; SNAKE VENOM; TEPROTIDE; THROMBIN; TIROFIBAN; TRIFLAVIN;

ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; BLEEDING; BLOOD CLOTTING; BRAIN ISCHEMIA; BREAST CANCER; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; HEMOSTASIS; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; METASTASIS INHIBITION; NONHUMAN; OVARY CANCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; SNAKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; PLATELET AGGREGATION INHIBITORS; SNAKE VENOMS;

SERPENTES;

EID: 80053639612     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.03.017     Document Type: Review

References (139)

1. Amininasab M., Elmi M.M., Endlich N., Endlich K., Parekh N., Naderi-Manesh H., Schaller J., Mostafavi H., Sattler M., Sarbolouki M.N., Muhle-Goll C. Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Lett. 2004, 557:104-108.
2. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
3. Bajwa S.S., Kirakossian H., Reddy K.N., Markland F.S. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes. Toxicon 1982, 20:427-432.
4. Barrett J.S., Murphy G., Peerlinck K., De L.I., Gould R.J., Panebianco D., Hand E., Deckmyn H., Vermylen J., Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 1994, 56:377-388.
5. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. 2003, 2:15-28.
6. Califf R.M. The rationale for thrombolytic therapy. Eur. Heart J. 1996, 17(Suppl. E):2-8.
7. Calvete J.J., Fox J.W., Agelan A., Niewiarowski S., Marcinkiewicz C. The presence of the WGD motif in CC8 heterodimeric disintegrin increases its inhibitory effect on alphaII(b)beta3, alpha(v)beta3, and alpha5beta1 integrins. Biochemistry 2002, 41:2014-2021.
8. Calvete J.J., Marcinkiewicz C., Monleon D., Esteve V., Celda B., Juarez P., Sanz L. Snake venom disintegrins: evolution of structure and function. Toxicon 2005, 45:1063-1074.
9. Castro H.C., Zingali R.B., Albuquerque M.G., Pujol-Luz M., Rodrigues C.R. Snake venom thrombin-like enzymes: from reptilase to now. Cell Mol. Life Sci. 2004, 61:843-856.
10. Chen H.H., Lainchbury J.G., Burnett J.C. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J. Am. Coll. Cardiol. 2002, 40:1186-1191.
11. Chen Y., Pitzenberger S.M., Garsky V.M., Lumma P.K., Sanyal G., Baum J. Proton NMR assignments and secondary structure of the snake venom protein echistatin. Biochemistry 1991, 30:11625-11636.
12. Chi C.W., Wang S.Z., Xu L.G., Wang M.Y., Lo S.S., Huang W.D. Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas). Peptides 1985, 6(Suppl. 3):339-342.
13. Clark E.A., Trikha M., Markland F.S., Brugge J.S. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. J. Biol. Chem. 1994, 269:21940-21943.
14. Clemetson K.J., Clemetson J.M. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb. Haemost 2008, 99:473-479.
15. Clemetson K.J., Lu Q., Clemetson J.M. Snake venom proteins affecting platelets and their applications to anti-thrombotic research. Curr. Pharm. Des 2007, 13:2887-2892.
16. Coelho A.L., De Freitas M.S., Mariano-Oliveira A., Rapozo D.C., Pinto L.F., Niewiarowski S., Zingali R.B., Marcinkiewicz C., Barja-Fidalgo C. RGD- and MLD-disintegrins, jarastatin and EC3, activate integrin-mediated signaling modulating the human neutrophils chemotaxis, apoptosis and IL-8 gene expression. Exp. Cell Res. 2004, 292:371-384.
17. Cushman D.W., Ondetti M.A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991, 17:589-592.
18. Cushman D.W., Ondetti M.A. Design of angiotensin converting enzyme inhibitors. Nat. Med. 1999, 5:1110-1113.
19. Cushman D.W., Ondetti M.A., Gordon E.M., Natarajan S., Karanewsky D.S., Krapcho J., Petrillo E.W. Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 1987, 10(Suppl. 7):S17-S30.
20. Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., Kostis J.B., Wilson A.C., Folsom A.R., Wu K., Benderly M., Goldbourt U., Willeit J., Kiechl S., Yarnell J.W., Sweetnam P.M., Elwood P.C., Cushman M., Psaty B.M., Tracy R.P., Tybjaerg-Hansen A., Haverkate F., de Maat M.P., Fowkes F.G., Lee A.J., Smith F.B., Salomaa V., Harald K., Rasi R., Vahtera E., Jousilahti P., Pekkanen J., D'Agostino R., Kannel W.B., Wilson P.W., Tofler G., Arocha-Pinango C.L., Rodriguez-Larralde A., Nagy E., Mijares M., Espinosa R., Rodriquez-Roa E., Ryder E., Diez-Ewald M.P., Campos G., Fernandez V., Torres E., Marchioli R., Valagussa F., Rosengren A., Wilhelmsen L., Lappas G., Eriksson H., Cremer P., Nagel D., Curb J.D., Rodriguez B., Yano K., Salonen J.T., Nyyssonen K., Tuomainen T.P., Hedblad B., Lind P., Loewel H., Koenig W., Meade T.W., Cooper J.A., De Stavola B., Knottenbelt C., Miller G.J., Cooper J.A., Bauer K.A., Rosenberg R.D., Sato S., Kitamura A., Naito Y., Palosuo T., Ducimetiere P., Amouyel P., Arveiler D., Evans A.E., Ferrieres J., Juhan-Vague I., Bingham A., Schulte H., Assmann G., Cantin B., Lamarche B., Despres J.P., Dagenais G.R., Tunstall-Pedoe H., Woodward M., Ben Shlomo Y., Davey S.G., Palmieri V., Yeh J.L., Rudnicka A., Ridker P., Rodeghiero F., Tosetto A., Shepherd J., Ford I., Robertson M., Brunner E., Shipley M., Feskens E.J., Kromhout D., Dickinson A., Ireland B., Juzwishin K., Kaptoge S., Lewington S., Memon A., Sarwar N., Walker M., Wheeler J., White I., Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
21. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
22. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981, 28:89-94.
23. de Mesquita L.C., Selistre H.S., Giglio J.R. The hypotensive activity of Crotalus atrox (western diamondback rattlesnake) venom: identification of its origin. Am. J. Trop. Med. Hyg. 1991, 44:345-353.
24. de Weille J.R., Schweitz H., Maes P., Tartar A., Lazdunski M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2437-2440.
25. Deitcher S.R., Toombs C.F. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase. Pathophysiol. Haemost. Thromb. 2005, 34:215-220.
26. Dickey D.M., Burnett J.C., Potter L.R. Novel bifunctional natriuretic peptides as potential therapeutics. J. Biol. Chem. 2008, 283:35003-35009.
27. Egbertson M.S., Chang C.T., Duggan M.E., Gould R.J., Halczenko W., Hartman G.D., Laswell W.L., Lynch J.J., Lynch R.J., Manno P.D. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37:2537-2551.
28. Eikelboom J.W., Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Haemost 2007, 5(Suppl. 1):255-263.
29. Evangelista J.S., Martins A.M., Nascimento N.R., Sousa C.M., Alves R.S., Toyama D.O., Toyama M.H., Evangelista J.J., Menezes D.B., Fonteles M.C., Moraes M.E., Monteiro H.S. Renal and vascular effects of the natriuretic peptide isolated from Crotalus durissus cascavella venom. Toxicon 2008, 52:737-744.
30. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
31. Ferreira L.A., Galle A., Raida M., Schrader M., Lebrun I., Habermehl G. Isolation: analysis and properties of three bradykinin-potentiating peptides (BPP-II, BPP-III, and BPP-V) from Bothrops neuwiedi venom. J. Protein Chem. 1998, 17:285-289.
32. Ferreira L.A., Mollring T., Lebrun F.L., Raida M., Znottka R., Habermehl G.G. Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom. Toxicon 1995, 33:1313-1319.
33. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br. J. Pharmacol. Chemother. 1965, 24:163-169.
34. Ferreira S.H., Bartelt D.C., Greene L.J. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 1970, 9:2583-2593.
35. Fox J.W., Serrano S.M. Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview of toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications. Curr. Pharm. Des 2007, 13:2927-2934.
36. Fry B.G., Wüster W., Kini R.M., Brusic V., Khan A., Venkataraman D., Rooney A.P. Molecular evolution and phylogeny of elapid snake venom three-finger toxins. Mol. Biol. Evol. 2003, 57:110-129.
37. Fry B.G., Wickramaratana J.C., Lemme S., Beuve A., Garbers D., Hodgson W.C., Alewood P. Novel natriuretic peptides from the venom of the inland taipan (Oxyuranus microlepidotus): isolation, chemical and biological characterisation. Biochem. Biophys. Res. Commun. 2005, 327:1011-1015.
38. Gan Z.R., Gould R.J., Jacobs J.W., Friedman P.A., Polokoff M.A. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J. Biol. Chem. 1988, 263:19827-19832.
39. Guerreiro J.R., Lameu C., Oliveira E.F., Klitzke C.F., Melo R.L., Linares E., Augusto O., Fox J.W., Lebrun I., Serrano S.M., Camargo A.C. Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production. J. Biol. Chem. 2009, 284:20022-20033.
40. Higuchi S., Murayama N., Saguchi K., Ohi H., Fujita Y., Camargo A.C., Ogawa T., Deshimaru M., Ohno M. Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom. Immunopharmacology 1999, 44:129-135.
41. Ho P.L., Soares M.B., Maack T., Gimenez I., Puorto G., Furtado M.F., Raw I. Cloning of an unusual natriuretic peptide from the South American coral snake Micrurus corallinus. Eur. J. Biochem. 1997, 250:144-149.
42. Huang T.F., Holt J.C., Lukasiewicz H., Niewiarowski S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J. Biol. Chem. 1987, 262:16157-16163.
43. Jackson C.M., Nemerson Y. Blood coagulation. Annu. Rev. Biochem. 1980, 49:765-811.
44. Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90:561-565.
45. Joseph R., Pahari S., Hodgson W.C., Kini R.M. Hypotensive agents from snake venoms. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4:437-459.
46. Joubert F.J., Taljaard N. The complete primary structures of two reduced and S-carboxymethylated Angusticeps-type toxins from Dendroaspis angusticeps (green mamba) venom. Biochim. Biophys. Acta 1980, 623:449-456.
47. Joubert F.J., Taljaard N. The primary structure of a short neurotoxin homologue (S4C8) from Dendroaspis jamesoni kaimosae (Jameson's mamba) venom. Int. J. Biochem. 1980, 12:567-574.
48. Kang I.C., Kim D.S., Jang Y., Chung K.H. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem. Biophys. Res. Commun. 2000, 275:169-173.
49. Kang I.C., Lee Y.D., Kim D.S. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res. 1999, 59:3754-3760.
50. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G., de Silva H.J. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS. Med. 2008, 5:e218.
51. Kato H., Suzuki T. Structure of bradykinin-potentiating peptide containing tryptophan from the venom of Agkistrodon halys blomhoffii. Experientia 1970, 26:1205-1206.
52. Kato H., Suzuki T. Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C. Biochemistry 1971, 10:972-980.
53. Kini R.M. Proline brackets and identification of potential functional sites in proteins: toxins to therapeutics. Toxicon 1998, 36:1659-1670.
54. Kini R.M. Platelet aggregation and exogenous factors from animal sources. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4:301-325.
55. Kini R.M. Serine proteases affecting blood coagulation and fibrinolysis from snake venoms. Pathophysiol. Haemost. Thromb. 2005, 34:200-204.
56. Kini R.M. Anticoagulant proteins from snake venoms: structure, function and mechanism. Biochem. J. 2006, 397:377-387.
57. 2+ channel binding site of calciseptine and FS2. Biochemistry 1998, 37:9058-9063.
58. Kini R.M., Evans H.J. A hypothetical structural role for proline residues in the flanking segments of protein-protein interaction sites. Biochem. Biophys. Res. Commun. 1995, 212:1115-1124.
59. Kini R.M., Evans H.J. Prediction of potential protein-protein interaction sites from amino acid sequence. Identification of a fibrin polymerization site. FEBS Lett. 1996, 385:81-86.
60. Kisiel D.G., Calvete J.J., Katzhendler J., Fertala A., Lazarovici P., Marcinkiewicz C. Structural determinants of the selectivity of KTS-disintegrins for the alpha1beta1 integrin. FEBS Lett. 2004, 577:478-482.
61. Kroll M.H., Schafer A.I. Biochemical mechanisms of platelet activation. Blood 1989, 74:1181-1195.
62. Lee C.Y., Burnett J.C. Natriuretic peptides and therapeutic applications. Heart Fail. Rev. 2007, 12:131-142.
63. Lee C.Y., Chen H.H., Lisy O., Swan S., Cannon C., Lieu H.D., Burnett J.C. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 2009, 49:668-673.
64. Leung L., Nachman R. Molecular mechanisms of platelet aggregation. Annu. Rev. Med. 1986, 37:179-186.
65. Levy D.E., del Zoppo G.J., Demaerschalk B.M., Demchuk A.M., Diener H.C., Howard G., Kaste M., Pancioli A.M., Spatareanu C., Wasiewski W.W. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 2009, 40:3796-3803.
66. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995, 47:25-49.
67. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., Burnett J.C. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 2008, 52:60-68.
68. Longhurst C.M., Jennings L.K. Integrin-mediated signal transduction. Cell Mol. Life Sci. 1998, 54:514-526.
69. Lu Q., Clemetson J.M., Clemetson K.J. Snake venoms and hemostasis. J. Thromb. Haemost 2005, 3:1791-1799.
70. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008, 451:914-918.
71. Marcinkiewicz C., Vijay-Kumar S., McLane M.A., Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site. Blood 1997, 90:1565-1575.
72. Marcinkiewicz C., Weinreb P.H., Calvete J.J., Kisiel D.G., Mousa S.A., Tuszynski G.P., Lobb R.R. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res. 2003, 63:2020-2023.
73. Markland F.S. Snake venoms and the hemostatic system. Toxicon 1998, 36:1749-1800.
74. Markland F.S., Shieh K., Zhou Q., Golubkov V., Sherwin R.P., Richters V., Sposto R. A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 2001, 31:183-191.
75. Markland F.S., Swenson S. Fibrolase and its evolution to clinical trials: a long and winding road. Toxins and Hemostasis: From Bench to Bedside 2010, 409-427. Springer, Dordrecht. R.M. Kini, K.J. Clemetson, F.S. Markland, M.A. McLane, T. Morita (Eds.).
76. Marsh N., Whaler B. The effects of snake venoms on the cardiovascular and haemostatic mechanisms. Int. J. Biochem. 1978, 9:217-220.
77. McLane M.A., Sanchez E.E., Wong A., Paquette-Straub C., Perez J.C. Disintegrins. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4:327-355.
78. McLane M.A., Vijay-Kumar S., Marcinkiewicz C., Calvete J.J., Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Lett. 1996, 391:139-143.
79. Michel G.H., Murayama N., Sada T., Nozaki M., Saguchi K., Ohi H., Fujita Y., Koike H., Higuchi S. Two N-terminally truncated forms of C-type natriuretic peptide from habu snake venom. Peptides 2000, 21:609-615.
80. Minea R., Swenson S., Costa F., Chen T.C., Markland F.S. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol. Haemost. Thromb. 2005, 34:177-183.
81. Moll S., Kenyon P., Bertoli L., De Maio J., Homesley H., Deitcher S.R. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J. Clin. Oncol. 2006, 24:3056-3060.
82. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99:6-38.
83. Mousa S.A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 2002, 6:534-541.
84. Murayama N., Hayashi M.A., Ohi H., Ferreira L.A., Hermann V.V., Saito H., Fujita Y., Higuchi S., Fernandes B.L., Yamane T., de Camargo A.C. Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1189-1193.
85. Nolan C., Hall L.S., Barlow G.H. Ancrod, the coagulating enzyme from Malayan pit viper (Agkistrodon rhodostoma) venom. Methods Enzymol. 1976, 45:205-213.
86. Novokhatny V. Structure and activity of plasmin and other direct thrombolytic agents. Thromb. Res. 2008, 122(Suppl. 3):S3-S8.
87. Olfa K.Z., Jose L., Salma D., Amine B., Najet S.A., Nicolas A., Maxime L., Raoudha Z., Kamel M., Jacques M., Jean-Marc S., Mohamed E.A., Naziha M. Lebestatin, a disintegrin from Macrovipera venom, inhibits integrin-mediated cell adhesion, migration and angiogenesis. Lab. Invest. 2005, 85:1507-1516.
88. Ondetti M.A. Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation 1988, 77:I74-I78.
89. Ondetti M.A., Cushman D.W. Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions. CRC Crit. Rev. Biochem. 1984, 16:381-411.
90. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196:441-444.
91. Ouriel K., Cynamon J., Weaver F.A., Dardik H., Akers D., Blebea J., Gruneiro L., Toombs C.F., Wang-Clow F., Mohler M., Pena L., Wan C.Y., Deitcher S.R. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J. Vasc. Interv. Radiol. 2005, 16:1075-1083.
92. Ozaki Y., Suzuki-Inoue K., Inoue O. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI. J. Thromb. Haemost. 2009, 7(Suppl. 1):191-194.
93. Packham M.A., Mustard J.F. The role of platelets in the development and complications of atherosclerosis. Semin. Hematol. 1986, 23:8-26.
94. Panchett A.A. The chemistry of enalapril. Br. J. Clin. Pharmacol. 1984, 18(Suppl. 2):201S-207S.
95. Patlak M. From viper's venom to drug design: treating hypertension. FASEB J. 2004, 18:421.
96. Peerlinck K., De L.I., Goldberg M., Farrell D., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993, 88:1512-1517.
97. Politi V., De Luca G., Di Stazio G., Schinina E., Bossa F. A new peptide from Crotalus atrox snake venom. Peptides 1985, 6(Suppl. 3):343-346.
98. Pu X.C., Wong P.T., Gopalakrishnakone P. A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon 1995, 33:1425-1431.
99. 2+ cation. Biochem. J. 1998, 335(Pt 2):247-257.
100. Randolph A., Chamberlain S.H., Chu H.L., Retzios A.D., Markland F.S., Masiarz F.R. Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci. 1992, 1:590-600.
101. Rijken D.C., Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost 2009, 7:4-13.
102. Sabia E.B., Tominaga M., Paiva A.C., Paiva T.B. Bradykinin potentiating and sensitizing activities of new synthetic analogues of snake venom peptides. J. Med. Chem. 1977, 20:1679-1681.
103. Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
104. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
105. Sanz L., Chen R.Q., Perez A., Hilario R., Juarez P., Marcinkiewicz C., Monleon D., Celda B., Xiong Y.L., Perez-Paya E., Calvete J.J. cDNA cloning and functional expression of jerdostatin, a novel RTS-disintegrin from Trimeresurus jerdonii and a specific antagonist of the alpha1beta1 integrin. J. Biol. Chem. 2005, 280:40714-40722.
106. Saudek V., Atkinson R.A., Pelton J.T. Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 1991, 30:7369-7372.
107. Saxenhofer H., Raselli A., Weidmann P., Forssmann W.G., Bub A., Ferrari P., Shaw S.G. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am. J. Physiol. 1990, 259:F832-F838.
108. Scarborough R.M., Naughton M.A., Teng W., Rose J.W., Phillips D.R., Nannizzi L., Arfsten A., Campbell A.M., Charo I.F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 1993, 268:1066-1073.
109. Scarborough R.M., Rose J.W., Hsu M.A., Phillips D.R., Fried V.A., Campbell A.M., Nannizzi L., Charo I.F. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 1991, 266:9359-9362.
110. Scarborough R.M., Rose J.W., Naughton M.A., Phillips D.R., Nannizzi L., Arfsten A., Campbell A.M., Charo I.F. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. 1993, 268:1058-1065.
111. Schaeffer R.C., Briston C., Chilton S.M., Carlson R.W. Hypotensive and hemostatic properties of rattlesnake (Crotalus viridis helleri) venom and venom fractions in dogs. J. Pharmacol. Exp. Ther. 1984, 230:393-398.
112. Schleifer K.J. Comparative molecular modelling study of the calcium channel blockers nifedipine and black mamba toxin FS2. J. Comput. Aided Mol. Des 1997, 11:491-501.
113. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 1992, 267:13928-13932.
114. Shah A.R., Scher L. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic. IDrugs 2007, 10:329-335.
115. Shebuski R.J., Ramjit D.R., Bencen G.H., Polokoff M.A. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J. Biol. Chem. 1989, 264:21550-21556.
116. Sherman D.G., Atkinson R.P., Chippendale T., Levin K.A., Ng K., Futrell N., Hsu C.Y., Levy D.E. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with Ancrod trial. JAMA 2000, 283:2395-2403.
117. Sheu J.R., Yen M.H., Kan Y.C., Hung W.C., Chang P.T., Luk H.N. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. Biochim. Biophys. Acta 1997, 1336:445-454.
118. Siang A.S., Doley R., Vonk F.J., Kini R.M. Transcriptomic analysis of the venom gland of the red-headed krait (Bungarus flaviceps) using expressed sequence tags. BMC Mol. Biol. 2010, 11:24.
119. Smith R.E., Ashiya M. Antihypertensive therapies. Nat. Rev. Drug Discov. 2007, 6:597-598.
120. St Pierre L., Flight S., Masci P.P., Hanchard K.J., Lewis R.J., Alewood P.F., de Jersey J., Lavin M.F. Cloning and characterisation of natriuretic peptides from the venom glands of Australian elapids. Biochimie 2006, 88:1923-1931.
121. Staniszewska I., Walsh E.M., Rothman V.L., Gaathon A., Tuszynski G.P., Calvete J.J., Lazarovici P., Marcinkiewicz C. Effect of VP12 and viperistatin on inhibition of collagen receptors-dependent melanoma metastasis. Cancer Biol. Ther. 2009, 8:1507-1516.
122. Stewart J.M., Ferreira S.H., Greene L.J. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem. Pharmacol. 1971, 20:1557-1567.
123. Stocker K., Barlow G.H. The coagulant enzyme from Bothrops atrox venom (batroxobin). Methods Enzymol. 1976, 45:214-223.
124. Strydom D.J. Snake venom toxins. The amino-acid sequence of a short-neurotoxin homologue from Dendroaspis polylepis polylepis (black mamba) venom. Eur. J. Biochem. 1977, 76:99-106.
125. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
126. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 1990, 168:863-870.
127. Swenson S., Costa F., Minea R., Sherwin R.P., Ernst W., Fujii G., Yang D., Markland F.S. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol. Cancer Ther. 2004, 3:499-511.
128. Swenson S., Toombs C.F., Pena L., Johansson J., Markland F.S. Alpha-fibrinogenases. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4:417-435.
129. Tibballs J. The cardiovascular, coagulation and haematological effects of tiger snake (Notechis scutatus) venom. Anaesth. Intensive Care 1998, 26:529-535.
130. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227-231.
131. Trikha M., De Clerck Y.A., Markland F.S. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. 1994, 54:4993-4998.
132. Warner R.L., McClintock S.D., Barron A.G., Iglesia de la Hemostatic properties of a venomic protein in rodent dermal injuries. Exp. Mol. Pathol. 2007, 83:241-248.
133. Watanabe T.X., Itahara Y., Kuroda H., Chen Y.N., Kimura T., Sakakibara S. Smooth muscle relaxing and hypotensive activities of synthetic calciseptine and the homologous snake venom peptide FS2. Jpn. J. Pharmacol. 1995, 68:305-313.
134. Wierzbicka-Patynowski I., Niewiarowski S., Marcinkiewicz C., Calvete J.J., Marcinkiewicz M.M., McLane M.A. Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. J. Biol. Chem. 1999, 274:37809-37814.
135. Yasuda O., Morimoto S., Jiang B., Kuroda H., Kimura T., Sakakibara S., Fukuo K., Chen S., Tamatani M., Ogihara T. FS2. a mamba venom toxin, is a specific blocker of the L-type calcium channels. Artery 1994, 21:287-302.
136. Yeh C.H., Peng H.C., Huang T.F. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood 1998, 92:3268-3276.
137. Yeh C.H., Peng H.C., Yang R.S., Huang T.F. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Mol. Pharmacol. 2001, 59:1333-1342.
138. Zhou Q., Nakada M.T., Brooks P.C., Swenson S.D., Ritter M.R., Argounova S., Arnold C., Markland F.S. Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. Biochem. Biophys. Res. Commun. 2000, 267:350-355.
139. Zhou Q., Sherwin R.P., Parrish C., Richters V., Groshen S.G., Tsao-Wei D., Markland F.S. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res. Treat. 2000, 61:249-260.